Specifications of a continual reassessment method design for phase I trials of combined drugs

被引:28
作者
Wages, Nolan A. [1 ]
Conaway, Mark R. [1 ]
机构
[1] Univ Virginia, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, VA USA
关键词
continual reassessment method; dose finding; maximum tolerated dose; phase I trials; partial ordering; drug combination; ADVANCED SOLID TUMORS; COMBINATIONS;
D O I
10.1002/pst.1575
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 18 条
  • [11] Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
    Patnaik, A
    Warner, E
    Michael, M
    Egorin, MJ
    Moore, MJ
    Siu, LL
    Fracasso, PM
    Rivkin, S
    Kerr, I
    Litchman, M
    Oza, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3677 - 3689
  • [12] Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase:: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors
    Ranson, M
    Middleton, MR
    Bridgewater, J
    Lee, SM
    Dawson, M
    Jowle, D
    Halbert, G
    Waller, S
    McGrath, H
    Gumbrell, L
    McElhinney, RS
    Donnelly, D
    McMurry, TBH
    Margison, GP
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (05) : 1577 - 1584
  • [13] Consistency of continual reassessment method under model misspecification
    Shen, LZ
    OQuigley, J
    [J]. BIOMETRIKA, 1996, 83 (02) : 395 - 405
  • [14] Using the time-to-event continual reassessment method in the presence of partial orders
    Wages, Nolan A.
    Conaway, Mark R.
    O'Quigley, John
    [J]. STATISTICS IN MEDICINE, 2013, 32 (01) : 131 - 141
  • [15] Dose-finding design for multi-drug combinations
    Wages, Nolan A.
    Conaway, Mark R.
    O'Quigley, John
    [J]. CLINICAL TRIALS, 2011, 8 (04) : 380 - 389
  • [16] Continual Reassessment Method for Partial Ordering
    Wages, Nolan A.
    Conaway, Mark R.
    O'Quigley, John
    [J]. BIOMETRICS, 2011, 67 (04) : 1555 - 1563
  • [17] A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
    Yin, Guosheng
    Yuan, Ying
    [J]. BIOMETRICS, 2009, 65 (03) : 866 - 875
  • [18] Bayesian dose finding in oncology for drug combinations by copula regression
    Yin, Guosheng
    Yuan, Ying
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2009, 58 : 211 - 224